214 related articles for article (PubMed ID: 2728396)
21. Kell sensitization in pregnancy.
Caine ME; Mueller-Heubach E
Am J Obstet Gynecol; 1986 Jan; 154(1):85-90. PubMed ID: 3946507
[TBL] [Abstract][Full Text] [Related]
22. Erythroblastosis fetalis with hydrops resulting from anti-Kell isoimmune disease.
Frigoletto FD; Davies IJ
Am J Obstet Gynecol; 1977 Apr; 127(8):887. PubMed ID: 851149
[No Abstract] [Full Text] [Related]
23. Successful treatment of extremely severe fetal anemia due to Kell alloimmunization.
Collinet P; Subtil D; Puech F; Vaast P
Obstet Gynecol; 2002 Nov; 100(5 Pt 2):1102-5. PubMed ID: 12423822
[TBL] [Abstract][Full Text] [Related]
24. [Hemolytic disease of the newborn caused by maternal allo-immunization against erythrocyte antigens other than A, B and rhesus D].
Monestier M; Rigal D; Juron-Dupraz F; Meyer F
J Gynecol Obstet Biol Reprod (Paris); 1984; 13(6):671-80. PubMed ID: 6520354
[TBL] [Abstract][Full Text] [Related]
25. Haemolytic disease of the newborn due to anti-K antibodies.
de Jonge N; Martens JE; Milani AL; Krijnen JL; van Krimpen C; Ponjee GA
Eur J Obstet Gynecol Reprod Biol; 1996 Jul; 67(1):69-72. PubMed ID: 8789754
[TBL] [Abstract][Full Text] [Related]
26. Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti-PP1Pk or anti-K immunization: a report of two patients.
Fernández-Jiménez MC; Jiménez-Marco MT; Hernández D; González A; Omeñaca F; de la Cámara C
Vox Sang; 2001 Feb; 80(2):117-20. PubMed ID: 11348543
[TBL] [Abstract][Full Text] [Related]
27. Death in utero due to Kell sensitization without excessive elevation of the delta OD450 value in amniotic fluid.
Berkowitz RL; Beyth Y; Sadovsky E
Obstet Gynecol; 1982 Dec; 60(6):746-9. PubMed ID: 7145281
[No Abstract] [Full Text] [Related]
28. Management of anti-Jka alloimmunization.
Franco A; Rossi K; Krugh D; O'Shaughnessy R
J Reprod Med; 2009 Mar; 54(3):121-5. PubMed ID: 19370894
[TBL] [Abstract][Full Text] [Related]
29. Impact of red blood cell alloimmunization on fetal and neonatal outcomes: A single center cohort study.
Lieberman L; Callum J; Cohen R; Cserti-Gazdewich C; Ladhani NNN; Buckstein J; Pendergrast J; Lin Y
Transfusion; 2020 Nov; 60(11):2537-2546. PubMed ID: 32893897
[TBL] [Abstract][Full Text] [Related]
30. Intravascular monitoring and management of erythroblastosis fetalis.
Berkowitz RL; Chitkara U; Wilkins IA; Lynch L; Plosker H; Bernstein HH
Am J Obstet Gynecol; 1988 Apr; 158(4):783-95. PubMed ID: 3284362
[TBL] [Abstract][Full Text] [Related]
31. Severe anti-C hemolytic disease of the newborn.
Bowman JM; Pollock JM; Manning FA; Harman CR
Am J Obstet Gynecol; 1992 Apr; 166(4):1239-43. PubMed ID: 1566777
[TBL] [Abstract][Full Text] [Related]
32. Obstetric outcome after RhD and Kell testing.
Lipitz S; Many A; Mitrani-Rosenbaum S; Carp H; Frenkel Y; Achiron R
Hum Reprod; 1998 Jun; 13(6):1472-5. PubMed ID: 9688374
[TBL] [Abstract][Full Text] [Related]
33. The near disappearance of fetal hydrops in relation to current state-of-the-art management of red cell alloimmunization.
Zwiers C; Oepkes D; Lopriore E; Klumper FJ; de Haas M; van Kamp IL
Prenat Diagn; 2018 Nov; 38(12):943-950. PubMed ID: 30187936
[TBL] [Abstract][Full Text] [Related]
34. Maternal Kell blood group alloimmunization.
Bowman JM; Pollock JM; Manning FA; Harman CR; Menticoglou S
Obstet Gynecol; 1992 Feb; 79(2):239-44. PubMed ID: 1731292
[TBL] [Abstract][Full Text] [Related]
35. [Isoimmunization to Kell factor, during pregnancy].
Krug A; Bianchi R; Cornejo A; Farias S; Fuentes L
Rev Chil Obstet Ginecol; 1988; 53(4):198-200. PubMed ID: 3155245
[No Abstract] [Full Text] [Related]
36. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.
Koelewijn JM; Vrijkotte TG; van der Schoot CE; Bonsel GJ; de Haas M
Transfusion; 2008 May; 48(5):941-52. PubMed ID: 18248570
[TBL] [Abstract][Full Text] [Related]
37. Treatment of fetal erythroblastosis by intravascular transfusions: outcome at 6 years.
Grab D; Paulus WE; Bommer A; Buck G; Terinde R
Obstet Gynecol; 1999 Feb; 93(2):165-8. PubMed ID: 9932548
[TBL] [Abstract][Full Text] [Related]
38. First case of hemolytic disease of the newborn due to anti-Ula antibodies.
Sakuma K; Suzuki H; Ohto H; Tsuneyama H; Uchikawa M
Vox Sang; 1994; 66(4):293-4. PubMed ID: 8079454
[TBL] [Abstract][Full Text] [Related]
39. A further example of anti-Di(b) not causing haemolytic disease of the newborn.
Habash J; Devenish A; Macdonald S; Garner S; Contreras M
Vox Sang; 1991; 61(1):77. PubMed ID: 1949717
[No Abstract] [Full Text] [Related]
40. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management.
Slootweg YM; Lindenburg IT; Koelewijn JM; Van Kamp IL; Oepkes D; De Haas M
Am J Obstet Gynecol; 2018 Oct; 219(4):393.e1-393.e8. PubMed ID: 30063902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
